The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1
Abstract
BACKGROUND: The use of antilymphocyte antibodies for induction therapy or for treatment for rejection has been associated with an increased risk of posttransplant lymphoproliferative disorder (PTLD). The authors investigated the incidence of PTLD after monoclonal antilymphocyte, polyclonal antilymphocyte, interleukin (IL)-2 receptor antibody, or no induction therapy in primary kidney transplant recipients. METHODS: A multivariate Cox analysis of 38,519 primary kidney transplants from January 1, 1997, to December 31, 2000, was performed to compare the incidence of PTLD, graft survival, and patient survival among the induction groups. RESULTS: The actual incidence of PTLD was 0.85% in 2,713 recipients with monoclonal, 0.81% in 4,343 with polyclonal, 0.50% in 7,800 with IL-2, and 0.51% in 23,663 recipients with no induction therapy (P=0.02). The Cox model indicated that as compared with no induction, the increased risk of PTLD was 72% with monoclonal (P=0.03), 29% with polyclonal (P=0.27), and 14% with IL-2 induction (P=0.52). IL-2 receptor antibody was associated with a 17% reduced risk of graft loss (P=0.002) and a 21% reduced risk of mortality (P=0.005) compared with no induction. Monoclonal and polyclonal induction therapies were not associated with a reduced risk of graft loss or mortality. Mycophenolate mofetil discharge maintenance immunosuppression was associated with a significantly reduced risk of PTLD and graft loss compared with azathioprine. CONCLUSIONS: Among induction therapies, IL-2 receptor antibody induction was associated with the smallest risk of PTLD and improved graft and patient survival. Monoclonal or polyclonal induction was not associated with improved graft or patient survival, and monoclonal induction was associated with an increased risk of PTLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Nashan, B., Moore, R., Amlot, P., Schmidt, A.-G., Abeywickrama, K., & Soulillou, J.-P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)09278-7 · Cited by 749
EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS
Paya, C. V., Fung, J. J., Nalesnik, M. A., Kieff, E., Green, M., Gores, G., Habermann, T. M., Wiesner, R. H., Swinnen, L. J., Woodle, E. S., et al. (1999) · Transplantation · doi:10.1097/00007890-199911270-00015 · Cited by 533
Self-citationKahan, B. D., Rajagopalan, P. R., & Hall, M. (1999) · Transplantation · doi:10.1097/00007890-199901270-00016 · Cited by 476
MYCOPHENOLATE MOFETIL REDUCES LATE RENAL ALLOGRAFT LOSS INDEPENDENT OF ACUTE REJECTION
Ojo, A. O., Meier-Kriesche, H.-U., Hanson, J. A., Leichtman, A. B., Cibrik, D., Magee, J. C., Wolfe, R. A., Agodoa, L. Y., & Kaplan, B. (2000) · Transplantation · doi:10.1097/00007890-200006150-00033 · Cited by 400
REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1
Nashan, B., Light, S., Hardie, I. R., Lin, A., & Johnson, J. R. (1999) · Transplantation · doi:10.1097/00007890-199901150-00019 · Cited by 302
Darenkov, I. A., Marcarelli, M. A., Basadonna, G. P., Friedman, A. L., Lorber, K. M., Howe, J. G., Crouch, J., Bia, M. J., Kliger, A. S., & Lorber, M. I. (1997) · Transplantation · doi:10.1097/00007890-199709270-00010 · Cited by 180
A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATION
Norman, D. J., Kahana, L., Stuart, F. P., Thistlethwaite, J. R., Shield, C. F., Monaco, A. P., Dehlinger, J., Wu, S.-C., HORN, A. V., & Haverty, T. P. (1993) · Transplantation · doi:10.1097/00007890-199301000-00009 · Cited by 154
Duvoux, C., Pageaux, G., Vanlemmens, C., Roudot-Thoraval, F. O., Vincens, A.-L., Hézode, C., Gaulard, P., Miguet, J., Larrey, D. G., Dhumeaux, D., et al. (2002) · Transplantation · doi:10.1097/00007890-200210270-00008 · Cited by 116
Center-Specific Graft and Patient Survival Rates
Lin, H., Kauffman, H. M., McBride, M., et al. (1998) · JAMA · doi:10.1001/jama.280.13.1153 · Cited by 94
Self-citation
Cited by
Malignancy after Transplantation
Buell, J. F., Gross, T. G., & Woodle, E. S. (2005) · Transplantation · doi:10.1097/01.tp.0000186382.81130.ba · Cited by 595
Humar, A., & Michaels, M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01207.x · Cited by 487
Cancer incidence and risk factors after solid organ transplantation
Vajdic, C. M., & van Leeuwen, M. T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24439 · Cited by 459
Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review
Gutierrez-Dalmau, A., & Campistol, J. M. (2007) · Drugs · doi:10.2165/00003495-200767080-00006 · Cited by 408
Metadata
- Authors
- Cherikh, W. S., Kauffman, H. M., McBride, M. A., Maghirang, J., Swinnen, L. J., & Hanto, D. W.
- Venue
- Transplantation
- Published
- 2003-11-15
- Volume
- 76
- Issue
- 9
- Pages
- 1289-1293
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1980998626
- Cited by
- 297
- References
- 11
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1. https://app.cochat.ai/papers/10.1097/01.tp.0000100826.58738.2b
- The paper
- Cherikh, W. S., Kauffman, H. M., McBride, M. A., Maghirang, J., Swinnen, L. J., & Hanto, D. W. (2003). Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1. Transplantation. https://doi.org/10.1097/01.tp.0000100826.58738.2b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.